Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D02PAW
|
||||
| Former ID |
DNCL002277
|
||||
| Drug Name |
TLC-388
|
||||
| Indication | Solid tumours [ICD9: 140-199, 210-229; ICD10:C00-D48] | Phase 2 | [1] | ||
| Company |
TLC Biopharmaceuticals
|
||||
| Structure |
|
Download2D MOL |
|||
| Target and Pathway | |||||
| Target(s) | Toposisomerase-1 | Target Info | Inhibitor | [1] | |
| NetPath Pathway | IL2 Signaling Pathway | ||||
| PANTHER Pathway | DNA replication | ||||
| Pathway Interaction Database | Caspase Cascade in Apoptosis | ||||
| WikiPathways | Integrated Pancreatic Cancer Pathway | ||||
| References | |||||
| REF 1 | Topotecan - A novel topoisomerase I inhibitor: pharmacology and clinical experience. Oncology. 1999;56(1):1-12. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.